Pages that link to "Q43135216"
Jump to navigation
Jump to search
The following pages link to Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems (Q43135216):
Displaying 23 items.
- An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. (Q26866314) (← links)
- Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC. (Q27311205) (← links)
- Neonatal -methamphetamine exposure in rats alters adult locomotor responses to dopamine D1 and D2 agonists and to a glutamate NMDA receptor antagonist, but not to serotonin agonists (Q30401457) (← links)
- Mouse pharmacological models of cognitive disruption relevant to schizophrenia (Q30457807) (← links)
- Drugs of abuse and increased risk of psychosis development. (Q34290364) (← links)
- A new strategy for antidepressant prescription (Q34371007) (← links)
- Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. (Q34378145) (← links)
- Pro-cognitive action of CART is mediated via ERK in the hippocampus. (Q34529569) (← links)
- Pharmacological enhancement of memory and executive functioning in laboratory animals. (Q34661221) (← links)
- Molecular Mechanism: ERK Signaling, Drug Addiction, and Behavioral Effects. (Q37671995) (← links)
- Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models. (Q37954123) (← links)
- Potential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits. (Q38344507) (← links)
- Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors (Q39153958) (← links)
- Pharmacological investigations of new galantamine peptide esters. (Q40733865) (← links)
- Tetrahydropalmatine protects against methamphetamine-induced spatial learning and memory impairment in mice (Q41442139) (← links)
- Role of convergent activation of glutamatergic and dopaminergic systems in the nucleus accumbens in the development of methamphetamine psychosis and dependence (Q43624965) (← links)
- Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance (Q47119261) (← links)
- Protein Kinase Cδ Gene Depletion Protects Against Methamphetamine-Induced Impairments in Recognition Memory and ERK1/2 Signaling via Upregulation of Glutathione Peroxidase-1 Gene. (Q48302307) (← links)
- Galantamine increases hippocampal insulin-like growth factor 2 expression via α7 nicotinic acetylcholine receptors in mice (Q48395191) (← links)
- Galantamine attenuates reinstatement of cue-induced methamphetamine-seeking behavior in mice (Q48703597) (← links)
- Galantamine promotes adult hippocampal neurogenesis via M₁ muscarinic and α7 nicotinic receptors in mice (Q87855334) (← links)
- Dopamine D3 receptor and GSK3β signaling mediate deficits in novel object recognition memory within dopamine transporter knockdown mice (Q92404899) (← links)
- Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia (Q96817727) (← links)